

# Alleviation of Alopecia after Switching from Escitalopram to Duloxetine: a Case Report

Sibel Kocbiyik<sup>1</sup>, Sedat Batmaz<sup>2</sup>,  
Levent Turhan<sup>3</sup>,  
Ozgur Ahmet Yuncu<sup>4</sup>, Ali Caykoylu<sup>5</sup>

<sup>1</sup>Ataturk Training and Research Hospital, Department of Psychiatry, Ankara - Turkey  
<sup>2</sup>Gaziosmanpasa University, Faculty of Medicine, Department of Psychiatry, Tokat - Turkey  
<sup>3</sup>Kartal Lutfi Kirdar Training and Research Hospital, Department of Psychiatry, Istanbul - Turkey  
<sup>4</sup>Ankara Training and Research Hospital, Department of Psychiatry, Ankara - Turkey  
<sup>5</sup>Yildirim Beyazıt University, Faculty of Medicine, Department of Psychiatry, Ankara - Turkey

## ABSTRACT

Alleviation of alopecia after switching from escitalopram to duloxetine: a case report

Many psychotropic drugs, including SSRIs, lithium, carbamazepine, valproate, vigabatrin, antipsychotics, benzodiazepines, and tricyclic antidepressants have been implicated in cases with alopecia. Drugs may cause a variety of dermatological side effects, ranging from mild hair loss to total alopecia, from hypertrichosis to hirsutism. In this paper, we present a case where alopecia emerged due to escitalopram, and where this side effect was alleviated after switching to duloxetine; we also review the literature for antidepressant-related alopecia.

**Keywords:** Alopecia, duloxetine, escitalopram

## ÖZET

Essitalopram kullanımıyla gelişen ve duloksetine geçilmesiyle gerileyen alopesi: Olgu sunumu

Seçici serotonin geri alım inhibitörleri (SSGİ), lityum, karbamazepin, valproik asit (sodyum valproat), vigabatrin, antipsikotikler, benzodiazepinler, trisiklik antidepresanlar da dahil olmak üzere bir çok psikotrop ilacın saç kaybı ile ilişkili olduğu bildirilmiştir. İlaçlar hafif saç dökülmesinden saçların tamamen kaybına, hipertrikozisten hirsutizme kadar birçok saç hastalığına neden olabilir. Bu yazıda essitalopram kullanımıyla gelişen ve duloksetin tedavisine geçilmesiyle saç dökülmesi yan etkisi gerileyen bir olgu sunulmuş ve antidepresanlara bağlı alopesi ile ilgili alanyazın gözden geçirilmiştir.

**Anahtar kelimeler:** Alopesi, duloksetin, essitalopram



Address reprint requests to / Yazışma adresi:  
Sedat Batmaz,  
Gaziosmanpasa University, Faculty of Medicine,  
Department of Psychiatry, Tokat, Turkey

Phone / Telefon: +90-356-214-9444/1290

Fax / Faks: +90-356-213-3179

E-mail address / Elektronik posta adresi:  
sedat.batmaz@gmail.com,  
sedat.batmaz@gop.edu.tr

Date of receipt / Geliş tarihi:  
April 5, 2015 / 5 Nisan 2015

Date of the first revision letter /  
İlk düzeltme öneri tarihi:  
April 13, 2015 / 13 Nisan 2015

Date of acceptance / Kabul tarihi:  
April 14, 2015 / 14 Nisan 2015

## INTRODUCTION

It has been reported that a number of psychotropic drugs, including Selective Serotonin Reuptake Inhibitors (SSRIs), lithium, carbamazepine, valproic acid (sodium valproate), vigabatrin, antipsychotics, benzodiazepines, and tricyclic antidepressants are related to hair loss (1-4). These drugs can cause trichopathies ranging from slight to complete hair loss and from hypertrichosis to hirsutism. Reason for these trichopathies is usually an increase or decrease of the speed of follicle proliferation due to the drugs. A follicle is a structure inside of which hair grows. It has been reported that hair loss occurs when drugs push follicles in the growth phase into the dormant phase. It is known that the life span of a follicle is three months.

Given that a follicle entering the dormant phase can no longer proliferate, it dies after three months and is shed. This is why drug-related hair loss is usually noticed in the third month (1,4). The term alopecia is used for all types of hair loss, from light hair loss to a total loss of body hair (1,4).

SSRIs are effective and safe drugs that have been used for many years to treat depression. Only few cases of SSRI-related alopecia have been reported in the literature. There are cases related to escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine, and citalopram (5-14). It has been reported that the incidence of this rarely seen side effect varies between SSRIs and is higher in women than in men (15). While alopecia is usually seen at the beginning of SSRI treatment, there have been rare cases seen after long-term treatment

(16). As they are seen more frequently with high doses, we can assume that this side effect is dose-related. Discontinuing the drug or reducing the dose usually results in a resumption of hair growth. Some researchers suggest that vitamin and mineral supplements may play a role in the improvement; however, sufficient evidence has not yet been found (1).

This report, which includes a brief review of the literature concerning SSRI-related alopecia, presents a case where with the discontinuation of escitalopram and the start of duloxetine treatment the side effect of hair loss remitted. The patient provided written informed consent.

## CASE

A 44-year-old married housewife applied to the polyclinic with complaints of low spirits, lack of motivation, difficulties of concentration, lack of appetite, and insomnia, which had been present for the past two months. The patient, who had no history of alcohol, cigarette, or substance use, was applying to the psychiatric polyclinic for the first time.

In the mental state examination, the patient was conscious and fully orientated, her speech spontaneous, thought process natural, her thinking included pessimistic content but no thoughts of suicide. No disorders regarding her general medical state were found.

With a diagnosis of first-episode major depressive disorder according to DSM 5 criteria, she was started on escitalopram 10mg/day. At control after one month, depressive symptoms had regressed and full remission been achieved. In the 3<sup>rd</sup> month of treatment, hair loss set in and became more evident in the 4<sup>th</sup> month. Liver, kidney, and thyroid function tests as well as full blood count were in the normal range. Other medical causes were excluded in a dermatological consultation. During this exclusion process, the dermatology department examined the case in detail and requested the necessary tests for potentially underlying thyroid pathologies, hormonal disorders, lack of minerals, and autoimmune diseases, but no pathological results were obtained. The dose of escitalopram was reduced to 5mg/day. At control another month later, it was seen that the patient

was still in remission and hair loss decreased; thus, it was recommended to stop the use of escitalopram. As the patient did not want to enter a period without medication, she was started on duloxetine 30mg/day, increased to 60mg/day one week later. At control in the following month, no alopecia was found and the signs of depression had not flared up again. In the 6<sup>th</sup> month of duloxetine treatment, the patient was still in remission, and no hair loss was found.

## DISCUSSION

In our case, it was thought that the developing alopecia was related to the use of escitalopram. It needs to be considered that other reasons to be excluded may be mental strain, substance use, diseases of the thyroid gland, kidneys, or liver, lack of iron, and malnutrition. Given that the patient's hair loss began in the remission phase, it was not assumed to be a bodily manifestation of mental strain. Examination results also did not point to the presence of trichotillomania in the patient. The dermatological consultation did not find any pathologies that might cause hair loss; the patient did not use any drugs other than escitalopram, and discontinuation of escitalopram improved the alopecia. Therefore, it was assumed that the alopecia was related with the drug.

To demonstrate the relation between alopecia and a drug, it is recommended to observe the regression of alopecia after stopping the drug and its resumption after starting the same drug (15). As the patient did not want to go into a period without medication, a treatment with duloxetine was initiated immediately after stopping escitalopram. Duloxetine was selected because no reported cases of alopecia with this drug were found.

A literature review showed that alopecia with SSRIs is mostly reported with sertraline, followed by citalopram (15). A patient file review for side effects made in Sweden found that in case reports corresponding to one million patient years each, there were 20.1 cases with sertraline and 4.5 cases with citalopram (15). However, we cannot assume these findings as evidence that these two SSRIs are causing a higher rate of alopecia. As these two SSRIs have been used for many years, it is possible that the higher number of case reports depends

on the more common use. In addition, the number of case reports is relatively low, and it is conceivable that a case may not have found its way into the literature. Therefore, it may be deceptive to focus on the number of cases reported for each SSRI until now. While there were cases improving with a reduction of dosage, there are also reports of improvement without dose reduction or even with an increase of the dose. Most of the reported cases are of women (14). This may be explained by the fact that women are using more SSRIs, are more concerned about their hair and more likely than men to report side effects regarding their hair to the doctor. In addition, the falling out of long hair is more noticeable. Nevertheless, we cannot exclude that SSRI-related alopecia is more common in women. A correlation has been found between blood serotonin level increase and alopecia (17). It may be assumed that SSRI-related alopecia is linked to a rise of serotonin.

## REFERENCES

- Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. *Ann Clin Psychiatry* 2000; 12:35-42. [\[CrossRef\]](#)
- Yucel A, Karakus G, Gunasti S. Dermatological side effects of psychotropic drugs and treatment approaches. *Bulletin of Clinical Psychopharmacology* 2008; 18:235-244. (Turkish)
- Warnock JK. Psychotropic medication and drug-related alopecia. *Psychosomatics* 1991; 32:149-152. [\[CrossRef\]](#)
- Gautam M. Alopecia due to psychotropic medications. *Ann Pharmacother* 1999; 33:631-637. [\[CrossRef\]](#)
- Pitchot W. Hair loss associated with escitalopram but not with venlafaxine: a case report. *Prim Care Companion CNS Disord* 2011; 13:1146. [\[CrossRef\]](#)
- Jenike MA. Severe hair loss associated with fluoxetine use. *Am J Psychiatry* 1991; 148:392. [\[CrossRef\]](#)
- Bhatara VS, Gupta S, Freeman JW. Fluoxetine associated paraesthesias and alopecia in a woman who tolerated sertraline. *J Clin Psychiatry* 1996; 57:227.
- Ghanizadeh A. Sertraline-associated hair loss. *J Drugs Dermatol* 2008; 7:693-694.
- Uzun O, Cansever A, Ozgen F. Hair loss due to sertraline use: a case report. *Bulletin of Clinical Psychopharmacology* 2003; 13:27-29. (Turkish)
- Zalsman G, Sever J, Munitz H. Hair loss associated with paroxetine treatment: a case report. *Clin Neuropharmacol* 1999; 22:246-247.
- Turkoglu S. Fluoxetine and sertraline related hair loss in a teenager: a case report. *Bulletin of Clinical Psychopharmacology* 2013; 23:77-80. [\[CrossRef\]](#)
- Mermi O, Atmaca M, Kilic F, Gurok MG, Kuloglu M. Fluoxetine Induced Hair Loss: a case report. *Dusunen Adam The Journal of Psychiatry and Neurological Sciences* 2014; 27:266-269. [\[CrossRef\]](#)
- Unal E, Mete L, Gulseren L, Elikucuk B. Hair loss related to the fluvoxamine use: case reports. *Reviews, cases and hypotheses in psychiatry (RHCP)* 2008; 1-2:63-66.
- Parameshwar E. Hair loss associated with fluvoxamine use. *Am J Psychiatry* 1996; 153:581-582. [\[CrossRef\]](#)
- Hedenmalm K, Sundström A, Spigset O. Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs). *Pharmacoepidemiol Drug Saf* 2006; 15:719-725. [\[CrossRef\]](#)
- Rais T, Singh T, Rais A. Hair loss associated with long-term sertraline treatment in teenager. *Psychiatry (Edgmont)* 2005; 2:52.
- Huang J, Gong Q, Li G, Lu S, Wang X. Serotonin in alopecia areata: an enzyme immunoassay study. *Int J Dermatol* 2004; 43:78-80. [\[CrossRef\]](#)

In conclusion, alopecia is a rarely seen side effect of SSRI. It is possible that the incidence varies for different SSRIs, and women may be more likely to develop this clinical presentation. If alopecia developing during SSRI therapy is thought to be a side effect related to the drug, it is to be considered to reduce the dose or change the antidepressant treatment.

Contribution Categories	Name of Author
Follow up of the case	S.K.
Literature review	S.K., S.B., L.T., O.A.Y., A.C.
Manuscript writing	S.K., S.B., L.T., O.A.Y., A.C.
Manuscript review and revision	S.K., S.B., L.T., O.A.Y., A.C.

**Conflict of Interest:** Authors declared no conflict of Interest.

**Financial Disclosure:** Authors declared no financial support.